180 related articles for article (PubMed ID: 16202599)
1. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
Jordan VC; Lewis JS; Osipo C; Cheng D
Breast; 2005 Dec; 14(6):624-30. PubMed ID: 16202599
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
3. Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.
Ariazi EA; Lewis-Wambi JS; Gill SD; Pyle JR; Ariazi JL; Kim HR; Sharma CG; Cordera F; Shupp HA; Li T; Jordan VC
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):128-38. PubMed ID: 17085047
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
5. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.
Swaby RF; Jordan VC
Clin Breast Cancer; 2008 Apr; 8(2):124-33. PubMed ID: 18621608
[TBL] [Abstract][Full Text] [Related]
6. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
Saji S; Kuroi K
Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal anti-estrogens in the treatment of breast cancer.
Barker S
Curr Opin Investig Drugs; 2006 Dec; 7(12):1085-91. PubMed ID: 17209526
[TBL] [Abstract][Full Text] [Related]
9. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
11. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
12. Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?
Scherbakov AM; Lobanova YS; Shatskaya VA; Onopchenko OV; Gershtein ES; Krasil'nikov MA
Breast Cancer Res Treat; 2006 Nov; 100(1):1-11. PubMed ID: 16990991
[TBL] [Abstract][Full Text] [Related]
13. Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A
Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
[TBL] [Abstract][Full Text] [Related]
14. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
Miller WR; Bartlett JM; Canney P; Verrill M
Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
[TBL] [Abstract][Full Text] [Related]
18. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
[TBL] [Abstract][Full Text] [Related]
19. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
[TBL] [Abstract][Full Text] [Related]
20. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
